$BLUE Form 8-K

0
695

Form 8-K for BLUEBIRD BIO, INC.


14-Dec-2016

Other Events, Financial Statements and Exhibits

Item 8.01 Other EventsOn December 14, 2016, bluebird bio, Inc. (“bluebird”) issued a press release announcing the treatment of the first subject in the Northstar-2 Study, bluebird’s global, multi-center Phase III study of its LentiGlobin product candidate for the treatment of patients with transfusion-dependent ?-thalassemia who do not have a ?0/?0 genotype.

The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.(d) Exhibits

Exhibit No. Description
99.1 Press release issued by bluebird bio, Inc. on December 14, 2016.

LEAVE A REPLY

Please enter your comment!
Please enter your name here